1
Thorsteinn Loftsson: Cyclodextrin complexation. Cyclops h f, Burns Doane Swecker & Mathis, December 5, 1995: US05472954 (73 worldwide citation)

The invention provides a method for enhancing the complexation of a cyclodextrin with a lipophilic and/or water-labile active ingredient which is a drug, cosmetic additive, food additive or agrochemical, comprising combining from about 0.1 to about 70% (weight/volume) of a cyclodextrin, from about 0 ...


2
Loftsson Thorsteinn: Cyclodextrin complexation.. Loftsson Thorsteinn, January 19, 1994: EP0579435-A1 (57 worldwide citation)

The invention provides a method for enhancing the complexation of a cyclodextrin with a lipophilic and/or water-labile drug, comprising combining from about 0.1 to about 70% (weight/volume) of a cyclodextrin and from about 0.001 to about 5% (weight/volume) of a pharmaceutically acceptable, pharmacol ...


3
Gianni Chessari, Christopher Norbert Johnson, Lee William Page, Ildiko Maria Buck, James Edward Harvey Day, Steven Howard, Gordon Saxty, Christopher William Murray: Bicyclic heterocycle compounds and their uses in therapy. ASTEX THERAPEUTICS, Heslin Rothenberg Farley & Mesiti P C, April 11, 2017: US09617248 (1 worldwide citation)

The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.


4
Gianni Chessari, Christopher Norbert Johnson, Lee William Page, Ildiko Maria Buck, James Edward Harvey Day, Steven Howard, Gordon Saxty, Christopher William Murray, Anna Hopkins: Bicyclic heterocycle compounds and their uses in therapy. ASTEX THERAPEUTICS, Heslin Rothenberg Farley & Mesiti P C, April 11, 2017: US09617283 (1 worldwide citation)

The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.


5
Gianni Chessari, Christopher Norbert Johnson, Lee William Page, Alessia Millemaggi, Steven Howard, Gordon Saxty, Thomas Daniel Heightman: Bicyclic heterocycle compounds and their uses in therapy. ASTEX THERAPEUTICS, Heslin Rothenberg Farley & Mesiti P C, May 30, 2017: US09663512

The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.


6
James Cloyd, Angela Birnbaum, Ilo Leppik, Stephen D Collins: Parenteral carbamazepine formulation. LUNDBECK PHARMACEUTICALS, Wilmer Cutler Pickering Hale and Dorr, April 25, 2017: US09629797

The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fl ...


7
James Cloyd, Angela Birnbaum, Ilo Leppik, Stephen D Collins: Parenteral carbamazepine formulation. LUNDBECK PHARMACEUTICALS, Wilmer Cutler Pickering Hale and Dorr, September 26, 2017: US09770407

The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fl ...


8
Mary Lynch, Melanie Kelly: Compositions and methods for treatment of ocular inflammation and/or pain. Bereskin & Parr S E N C R L s r l, Noel Courage, January 24, 2017: US09549906

The disclosure provides methods of treatment of ocular inflammation and/or neuropathic pain in a subject in need thereof, comprising administering to the subject in need thereof a CB2 target agent, a cannabimimetic agent or a combination thereof. The agent is optionally a cannabinoid, such as a non- ...


9
Paul W T J Leufkens: 2-iminobiotin formulations and uses thereof. Neurophyxia, Traskbritt P C, April 11, 2017: US09616135

The disclosure relates to improving the aqueous solubility of 2-iminobiotin. In a particular aspect, the disclosure pertains to formulations suitable for administration of 2-iminobiotin to mammals suffering from disorders or conditions that benefit from that administration.


10
Jinming Gao, David Boothman, Yinjian Zhou, Erik Bey: PH-sensitive compositions for delivery of beta lapachone and methods of use. The Board of Regents of the University of Texas System, Parker Highlander PLLC, April 25, 2017: US09631041

Disclosed herein are compounds comprising a polymer conjugated with a pH-sensitive prodrug of beta-lapachone, wherein the compound is capable of forming a micelle, and wherein the pH-sensitive prodrug comprises a pH-sensitive linker selected from the group consisting of: an aryl imine and an aliphat ...



Click the thumbnails below to visualize the patent trend.